Skip to main content

Table 2 Competing risks regression analysis with separate inclusion of the lymph node ratio (LNR) and pN stage as a covariate

From: The lymph node ratio predicts cancer-specific survival of node-positive non-small cell lung cancer patients: a population-based SEER analysis

Characteristics SHR P SHR P
LNR classification
 LNR1 1(Reference)    
 LNR2 1.56 (1.47–1.67) < 0.001   
 LNR3 2.54 (2.30–2.80) < 0.001   
N stage
 N1    1 (Reference)  
 N2    1.54 (1.45–1.63) < 0.001
 N3    2.81 (2.32–3.41) < 0.001
Sex
 Female 1(Reference)   1(Reference)  
 Male 1.23 (1.16–1.30) < 0.001 1.21 (1.134–1.29) < 0.001
Race
 White 1(Reference)   1(Reference)  
 Black 0.94 (0.85–1.05) 0.262 0.97 (0.87–1.07) 0.506
 Others 0.90 (0.81–1.00) 0.040 0.88 (0.79–0.98) 0.020
Primary site
 Upper lobe 1(Reference)   1(Reference)  
 Lowerlobe 1.08 (1.01–1.15) 0.018 1.11 (1.04–1.18) 0.001
 Mainbronchus 1.20 (0.96–1.49) 0.103 1.21 (0.98–1.51) 0.083
 Middlelobe 0.93 (0.81–1.06) 0.290 1.03 (0.91–1.18) 0.625
 Overlapping/NOS 1.28 (1.10–1.49) 0.001 1.30 (1.12–1.52) < 0.001
Grade
 I/II 1(Reference)   1(Reference)  
 III/IV 1.23 (1.16–1.31) < 0.001 1.25 (1.18–1.33) < 0.001
Histology
 Adenocarcinoma 1(Reference)   1(Reference)  
 Squamous 0.92 (0.86–0.99)   0.91 (0.84–0.97) 0.008
 Others 1.15 (1.05–1.25) 0.002 1.14 (1.04–1.24) 0.003
T stage   0.030   
 T1 1(Reference)    
 T2 1.32 (1.23–1.412) < 0.001 1.29 (1.199–1.38) < 0.001
 T3 1.85 (1.62–2.12) < 0.001 1.78 (1.56–2.04) < 0.001
 T4 1.82 (1.64–2.01) < 0.001 1.82 (1.64–2.01) < 0.001
  1. LNR Lymph node ratio, SHR sub-distribution hazards ratio
\